Amount of qualified individuals: CDEC mentioned the uncertainty in the amount of patients with reasonably critical to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some people that are labeled as possessing mild or average ailment might have a severe bleeding phenotype, https://christianx356rsv1.blog5star.com/profile